Question 6 of 6: Mechanical vs. Biological Heart Valves and Patient-Specific Selection

Question 6: Mechanical vs. Biological Heart Valves and Patient-Specific Selection (20 marks)

Question text not reproduced: the examination questions are © Engineers and Geoscientists BC. Open the official past paper (linked at the top of this page) to read the question, then follow the worked solution below.

(a) Mechanical valves (e.g., bileaflet pyrolytic-carbon designs) are essentially unlimited in mechanical durability — a well-functioning mechanical valve can be expected to last the rest of a patient's life without structural failure — and give consistent, well-characterized hemodynamic performance. Their major drawback is that the same rigid, synthetic, blood-contacting surfaces that give them durability are also thrombogenic (recall the surface–protein–platelet cascade of Question 1), so every mechanical-valve recipient requires lifelong systemic anticoagulation (typically warfarin), which carries its own ongoing bleeding risk, requires regular blood monitoring, and is unsuitable for patients who cannot reliably manage anticoagulation therapy or who have a high independent bleeding risk. Bioprosthetic (biological) valves — chemically fixed porcine valves or bovine pericardial tissue, or human homografts — use a tissue leaflet that is far less thrombogenic, so most recipients avoid the need for lifelong anticoagulation, and their hemodynamics more closely resemble a native valve. Their major drawback is limited durability: the fixed tissue undergoes progressive structural degeneration and calcification, typically failing within 10–15 years, and this degeneration is markedly faster in younger patients (whose higher metabolic/calcium turnover accelerates tissue calcification), which is the central trade-off in part (b).

(b) For the 50-year-old male, remaining life expectancy substantially exceeds the 10–15 year durability window of a bioprosthetic valve, so a bioprosthetic choice would very likely commit this patient to at least one, and possibly more, high-risk repeat open-heart (or transcatheter valve-in-valve) reoperations over his lifetime; a 50-year-old is also typically a good candidate for reliable long-term anticoagulation management (lower baseline fall/bleeding risk than an elderly patient, generally fewer comorbidities and drug interactions). The mechanical valve's durability therefore outweighs the anticoagulation burden, and a mechanical valve is recommended. For the 80-year-old female, remaining life expectancy is likely at or below the bioprosthetic durability window, so the tissue valve is likely to outlast her without ever needing replacement; conversely, lifelong anticoagulation carries disproportionately higher risk in an elderly patient (higher fall risk, higher incidence of major bleeding, more comorbidities and polypharmacy interacting with warfarin), and her comparatively lower peak physical activity level makes the mechanical valve's durability advantage less clinically valuable. A bioprosthetic valve is recommended, avoiding lifelong anticoagulation risk in a patient for whom it offers little corresponding lifetime benefit.